Kinetic Software Library
Monebo Technologies, Inc. · Decision date Oct 23, 2026
What did the FDA decide?
FDA recorded a substantially equivalent (SESE) decision on October 23, 2026 for the Kinetic Software Library, submitted by Monebo Technologies, Inc. under K260640. The device is an electrocardiograph software library (21 CFR 870.2340, Class II, product code DPS) intended for integration into a client's ECG device through an API; the summary states it has no user interface and produces no physical report. The listed predicate is Monebo's Automated ECG Analysis and Interpretation Software Library (K062282).
The summary describes signal processing and analysis functions including QRS detection, ectopic beat detection, QRS feature extraction, heart rate measurement and rhythm analysis, and states the library is not intended for life-supporting systems or ECG monitoring and alarm devices. The public record does not include the decision statement text, so the basis for the equivalence finding is not established here; the summary's comparison tables and the applicant's conclusion are not independent FDA findings.
- Regulatory pathway
- 510(k) premarket notification
- Clinical specialty
- Cardiovascular
- Decision date
- Oct 23, 2026
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- K260640
- Regulatory pathway
- 510(k) premarket notification
- Applicant
- Monebo Technologies, Inc.
- Product code
- DPS
- Decision code
- SESE
- Decision date
- Oct 23, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Electrocardiograph.
- Applicant
- Monebo Technologies, Inc.
- Product code
- DPS
- FDA device class
- 2
FDA decision timeline
K260640 received
Application receipt date recorded by FDA.
K260640 · FDA decision
SESE
Related devices and submissions
Explore the linked device profile
Other records with product code DPS
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| HeartSciences, Inc. | 510(k) clearance | Oct 5, 2026 | FDA | |
| QT Medical, Inc. | 510(k) clearance | Sep 29, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Monebo Technologies, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Austin, TX
Sources and methodology
- Original FDA record: K260640
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records